What is Wicab?
Wicab, operating at the intersection of neuroscience and assistive technology, is the developer of the BrainPort platform. The company specializes in sensory substitution devices, most notably the BrainPort Vision Pro, which translates visual data into tactile stimulation on the tongue, allowing the profoundly blind to perceive their environment. Furthermore, the BrainPort Balance Plus serves as a critical biofeedback tool for individuals suffering from vestibular dysfunction. By focusing on neuroplasticity and human-computer interface innovation, Wicab occupies a unique niche in the health-tech sector, providing life-altering independence to users through non-invasive, hardware-enabled software solutions.
How much funding has Wicab raised?
Wicab has raised a total of $7.4M across 3 funding rounds:
Multiple Rounds
$7.4M
Private Equity (2016): $974K, investors not publicly disclosed
Series A (2016): $2.4M, investors not publicly disclosed
Series B (2016): $4M, investors not publicly disclosed
Key Investors in Wicab
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Wicab?
With the recent infusion of capital, Wicab is expected to prioritize the expansion of its clinical trial pipeline and the scaling of its manufacturing capabilities to meet growing demand for its assistive devices. The company's strategic roadmap likely includes deepening its regulatory footprint in international markets and refining its sensory-substitution algorithms to enhance user resolution and device ergonomics. As Wicab moves into this next phase of growth, the focus will remain on securing long-term partnerships with healthcare providers and insurance networks to ensure broader accessibility to its life-enhancing technologies, ultimately solidifying its leadership in the assistive hardware ecosystem.
See full Wicab company page
